Assembly Biosciences (NASDAQ:ASMB) Upgraded to Strong-Buy at Wall Street Zen

Assembly Biosciences (NASDAQ:ASMB) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Sunday.

Several other brokerages have also issued reports on ASMB. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Assembly Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $41.75.

Assembly Biosciences Trading Down 4.1%

Shares of NASDAQ:ASMB opened at $27.70 on Friday. The firm has a market capitalization of $439.41 million, a PE ratio of -37.43 and a beta of 1.11. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $39.71. The business’s 50 day moving average is $27.93 and its 200-day moving average is $29.79.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99. The business had revenue of $42.47 million during the quarter, compared to analyst estimates of $7.42 million. Assembly Biosciences had a negative return on equity of 5.63% and a negative net margin of 8.47%. On average, sell-side analysts predict that Assembly Biosciences will post -6.87 EPS for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP acquired a new stake in Assembly Biosciences in the 4th quarter valued at $147,000. Virtus Investment Advisers LLC bought a new stake in Assembly Biosciences in the fourth quarter valued at $251,000. Susquehanna Portfolio Strategies LLC acquired a new position in Assembly Biosciences during the fourth quarter worth $473,000. Superstring Capital Management LP bought a new position in shares of Assembly Biosciences during the fourth quarter valued at $2,220,000. Finally, Millennium Management LLC lifted its holdings in shares of Assembly Biosciences by 354.6% during the fourth quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock valued at $3,340,000 after acquiring an additional 76,613 shares during the period. Institutional investors own 19.92% of the company’s stock.

Key Stories Impacting Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $50 target, which supports investor upside expectations. Article Title
• Positive Sentiment: The firm raised FY2026 estimates sharply (to $1.61 EPS) and put a large $3.51 EPS estimate for Q4‑2026 — signals HC Wainwright sees material near‑term revenue/earnings drivers that could deliver a positive earnings surprise in late 2026.
• Positive Sentiment: HC Wainwright also raised FY2028 estimates (to $0.32 EPS), suggesting a view that Assembly’s longer‑term pipeline/commercial prospects can generate positive earnings beyond the immediate quarters.
• Neutral Sentiment: The report includes a suite of multi‑year projections (Q1–Q4 2027, FY2030 estimates such as $3.23 EPS for FY2030) that provide modeling guidance but are farther out and carry higher uncertainty for near‑term stock moves.
• Negative Sentiment: HC Wainwright cut Q1, Q2 and Q3 2026 estimates (to roughly ($0.73), ($0.71), ($0.69) EPS respectively), indicating weaker expected near‑term performance that can pressure the stock until the company shows improving quarterly results.
• Negative Sentiment: The firm lowered FY2027 and FY2029 forecasts materially (FY2027 to ($0.64) from $1.44; FY2029 to ($2.83) from $3.09), pointing to increased downside risk in certain outyears and greater forecast volatility that can weigh on sentiment.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.